Skip to main content

Table 2 Demographic and clinical features of control groups

From: Ceruloplasmin functional changes in Parkinson’s disease-cerebrospinal fluid

 

H

PN

 

Sex

Age at examination

[C] mg/ml

Sex

Age at examination

[C] mg/ml

Diagnosis

#1

F

70

0.34

F

50

0.23

pnp-infl

#2

M

72

0.32

F

60

0.35

pnp-infl

#3

M

76

0.36

F

69

0.75

pnp-infl

#4

F

43

0.21

M

46

0.45

pnp-idio

#5

M

54

0.25

M

75

0.26

pnp-infl

#6

M

72

0.27

M

50

0.58

pnp-infl

#7

M

46

0.47

M

80

0.41

pnp-idio

#8

F

62

0.34

F

39

0.41

pnp-infl

#9

M

78

0.53

M

31

0.77

pnp-infl

#10

F

59

0.35

M

35

0.51

pnp-tox

#11

M

81

0.47

F

64

0.32

pnp-tox

#12

M

76

0.52

    

#13

M

82

0.43

    

#14

F

69

0.28

    

#15

M

73

0.57

    

#16

F

78

0.77

    
 

10 M/6 F

68.2 ± 12

0.41 ± 0.15

6 M/5 F

54.5 ± 16.4

0.46 ± 0.18

 
  

m ± sd

m ± sd

 

m ± sd

m ± sd

 
  1. H = healthy subjects; PN = peripheral neuropathies; [C] mg/ml = CSF total protein concentration; m = mean; sd = standard deviation; pnp-infl = peripheral neuropathy inflammatory; pnp-idio = pnp-idiopathic; pnp-tox = pnp-toxic